Takis S.r.l.

Università Degli Studi Di Roma "la Sapienza"

Istituti Fisioterapici Ospitalieri

Istituto Nazionale Tumori Irccs “fondazione G. Pascale”

Rita Mancini

Gennaro Ciliberto

Luigi Aurisicchio

Emanuele Marra

Guiseppe Roscilli

Paolo Antonio Ascierto

Luigi Fattore

Gerardo Botti

miRNAs for in vitro diagnosis of resistance of tumors to BRAF/MEK pathway (also named as MAPK 5 pathway) inhibiting drugs and for treatment of tumors which are treated with said drugs, such as melanoma, by stimulating or inhibiting the expression of down-regulated or up-regulated miRNAs, respectively.

MiRNAs for treatment and in vitro diagnosis of drug resistant tumors

The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.

Immunotherapy against ErbB-3 receptor

Growing community of inventors

Rome, Italy

Rita Mancini